Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

Cedars-Sinai experts believe the study's findings can play a crucial role in developing healthcare policies that promote ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

These include commonly prescribed drugs such as Ozempic or Wegovy (semaglutide), Saxenda (liraglutide), Zepbound (tirzepatide ...

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy.

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may ...

Image Credit: Alones/Shutterstock.com In a recent study published in JAMA Network Open, researchers from the United States of ...

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ...

Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to ...

Researchers examine the association between prescriptions of diabetes drugs and the incidence of alcohol intoxication and ...